About Catalyst Pharmaceuticals, Inc.
https://www.catalystpharma.comCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.
CEO
Richard John Daly
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 204
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:18.69M
Value:$433.16M
BLACKROCK, INC.
Shares:18.22M
Value:$422.07M
VANGUARD GROUP INC
Shares:8.71M
Value:$201.89M
Summary
Showing Top 3 of 419
About Catalyst Pharmaceuticals, Inc.
https://www.catalystpharma.comCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $148.39M ▲ | $56.81M ▲ | $52.78M ▲ | 35.57% ▲ | $0.43 | $80.45M ▲ |
| Q2-2025 | $146.56M ▲ | $50.31M ▼ | $52.11M ▼ | 35.55% ▼ | $0.43 ▼ | $78.75M ▲ |
| Q1-2025 | $141.42M ▼ | $60.14M ▲ | $56.74M ▲ | 40.12% ▲ | $0.47 | $72.83M ▲ |
| Q4-2024 | $141.82M ▲ | $57.33M ▼ | $55.94M ▲ | 39.44% ▲ | $0.47 ▲ | $72.3M ▲ |
| Q3-2024 | $128.69M | $58.51M | $43.88M | 34.1% | $0.37 | $50.91M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $689.89M ▲ | $1.05B ▲ | $131.36M ▲ | $920.25M ▲ |
| Q2-2025 | $652.8M ▲ | $971.91M ▲ | $115.89M ▲ | $856.03M ▲ |
| Q1-2025 | $580.66M ▲ | $908.87M ▲ | $114.59M ▼ | $794.28M ▲ |
| Q4-2024 | $517.55M ▲ | $851.41M ▲ | $123.78M ▲ | $727.63M ▲ |
| Q3-2024 | $442.33M | $772.01M | $111.07M | $660.94M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $52.78M ▲ | $32.44M ▼ | $0 ▲ | $4.65M ▲ | $37.09M ▼ | $32.44M ▼ |
| Q2-2025 | $52.11M ▼ | $71.3M ▲ | $-26K ▼ | $872K ▼ | $72.14M ▲ | $71.27M ▲ |
| Q1-2025 | $56.74M ▲ | $60.04M ▼ | $0 ▲ | $3.06M ▼ | $63.1M ▼ | $60.04M ▼ |
| Q4-2024 | $55.94M ▲ | $70.88M ▼ | $-88K ▲ | $4.43M ▲ | $75.22M ▲ | $70.79M ▼ |
| Q3-2024 | $43.88M | $72.87M | $-259K | $-5.97M | $66.64M | $72.61M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 License And Other Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Product Revenue Net | $260.00M ▲ | $140.00M ▼ | $150.00M ▲ | $150.00M ▲ |
CEO
Richard John Daly
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 204
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:18.69M
Value:$433.16M
BLACKROCK, INC.
Shares:18.22M
Value:$422.07M
VANGUARD GROUP INC
Shares:8.71M
Value:$201.89M
Summary
Showing Top 3 of 419